RxDoctor Payments Data

Alan Nichols

Acute Care · Clyde, TXNPI 1144283664

Payments from drug & device makers

$486in general payments, 2019–2025

Across 29 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$133
  • AbbVie$83
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$61
  • Novo Nordisk$46
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21
  • Neurocrine Biosciences, Inc.$21
  • plus $122 from 8 others

What the payments were for

  • Food & beverage$486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$486 in reported general payments places this provider in the 55th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$4,687
Medicare patients
61
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol102$83,478
Invega SustennaPaliperidone Palmitate15$54,021
JardianceEmpagliflozin36$40,968
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$33,116
TrulicityDulaglutide18$19,033
Bydureon BciseExenatide Microspheres21$18,090
TradjentaLinagliptin20$14,122
OzempicSemaglutide14$13,378
JanuviaSitagliptin Phosphate18$10,419
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$8,339
Icosapent Ethyl14$5,685
Fesoterodine Fumarate ErFesoterodine Fumarate37$4,906
Oxcarbazepine39$4,320
SymbicortBudesonide/Formoterol Fumarate13$4,125
Levothyroxine Sodium328$3,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$133$87,604115 claims
Lilly USA, LLCTrulicity$14$19,03318 claims
Novo NordiskOzempic$46$13,37814 claims
MerckJanuvia$12$10,41918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,323 acute care providers in Texas.

Other acute care in Clyde

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →